Mabwell Receives Regulatory Clearance for Clinical Trial of 9MW5211 Injection Targeting Type 1 Diabetes

Stock News07-07

Mabwell (Shanghai) Bioscience Co., Ltd. (ASX: 688062) has announced that it has received a clinical trial approval notice from the National Medical Products Administration.

The approval pertains to the application for a clinical trial of the 9MW5211 injection for the Type 1 Diabetes Mellitus (T1DM) indication.

Previously, clinical trial applications for this same injection for the Inflammatory Bowel Disease (IBD) indication have been approved by both China's NMPA and the U.S. FDA, while its application for the Multiple Sclerosis (MS) indication has also received NMPA approval.

9MW5211 is a highly specific, depleting novel antibody independently developed by the company. It is designed to precisely target the key pathological mechanisms mediated by abnormal immune cells in autoimmune diseases.

The aberrant activation and tissue infiltration of immune cells are central drivers in the development and progression of numerous autoimmune conditions.

The molecule targeted by 9MW5211 is specifically expressed on the surface of pathogenic immune cells, serving as a critical biological marker for their abnormal activation.

By selectively recognizing and clearing these pathogenic cells, 9MW5211 can effectively block the immune cascade, thereby alleviating disease progression and improving clinical symptoms.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199596221?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-07 20:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199596221","market":"sh","top_or_hot":-1,"title":"Mabwell Receives Regulatory Clearance for Clinical Trial of 9MW5211 Injection Targeting Type 1 Diabetes","media":"Stock News","content":"<p>Mabwell (Shanghai) Bioscience Co., Ltd. (<b>ASX: 688062</b>) has announced that it has received a clinical trial approval notice from the National Medical Products Administration.<br><br>The approval pertains to the application for a clinical trial of the 9MW5211 injection for the Type 1 Diabetes Mellitus (T1DM) indication.<br><br>Previously, clinical trial applications for this same injection for the Inflammatory Bowel Disease (IBD) indication have been approved by both China's NMPA and the U.S. FDA, while its application for the Multiple Sclerosis (MS) indication has also received NMPA approval.<br><br>9MW5211 is a highly specific, depleting novel antibody independently developed by the company. It is designed to precisely target the key pathological mechanisms mediated by abnormal immune cells in autoimmune diseases.<br><br>The aberrant activation and tissue infiltration of immune cells are central drivers in the development and progression of numerous autoimmune conditions.<br><br>The molecule targeted by 9MW5211 is specifically expressed on the surface of pathogenic immune cells, serving as a critical biological marker for their abnormal activation.<br><br>By selectively recognizing and clearing these pathogenic cells, 9MW5211 can effectively block the immune cascade, thereby alleviating disease progression and improving clinical symptoms.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mabwell Receives Regulatory Clearance for Clinical Trial of 9MW5211 Injection Targeting Type 1 Diabetes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMabwell Receives Regulatory Clearance for Clinical Trial of 9MW5211 Injection Targeting Type 1 Diabetes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-07 20:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mabwell (Shanghai) Bioscience Co., Ltd. (<b>ASX: 688062</b>) has announced that it has received a clinical trial approval notice from the National Medical Products Administration.<br><br>The approval pertains to the application for a clinical trial of the 9MW5211 injection for the Type 1 Diabetes Mellitus (T1DM) indication.<br><br>Previously, clinical trial applications for this same injection for the Inflammatory Bowel Disease (IBD) indication have been approved by both China's NMPA and the U.S. FDA, while its application for the Multiple Sclerosis (MS) indication has also received NMPA approval.<br><br>9MW5211 is a highly specific, depleting novel antibody independently developed by the company. It is designed to precisely target the key pathological mechanisms mediated by abnormal immune cells in autoimmune diseases.<br><br>The aberrant activation and tissue infiltration of immune cells are central drivers in the development and progression of numerous autoimmune conditions.<br><br>The molecule targeted by 9MW5211 is specifically expressed on the surface of pathogenic immune cells, serving as a critical biological marker for their abnormal activation.<br><br>By selectively recognizing and clearing these pathogenic cells, 9MW5211 can effectively block the immune cascade, thereby alleviating disease progression and improving clinical symptoms.<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688062","symbol_name":"迈威生物-U","start_time":0,"source_url":"","article_id":"1199596221","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199596221","pubTimestamp":1783426792,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Mabwell (Shanghai) Bioscience Co., Ltd. (ASX: 688062) has announced that it has received a clinical trial approval notice from the National Medical Products Administration.The approval pertains to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688062":"迈威生物-U","02493":"迈威生物-B","BMED":"iShares Health Innovation Active ETF","BK1161":"生物科技","IBBQ":"Invesco Nasdaq Biotechnology ETF","BK0239":"医药制造"},"translate_title":"Mabwell获得监管机构批准9MW5211注射液靶向1型糖尿病的临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688062":1,"BMED":1,"02493":1,"IBBQ":1},"content_text":"Mabwell (Shanghai) Bioscience Co., Ltd. (ASX: 688062) has announced that it has received a clinical trial approval notice from the National Medical Products Administration.The approval pertains to the application for a clinical trial of the 9MW5211 injection for the Type 1 Diabetes Mellitus (T1DM) indication.Previously, clinical trial applications for this same injection for the Inflammatory Bowel Disease (IBD) indication have been approved by both China's NMPA and the U.S. FDA, while its application for the Multiple Sclerosis (MS) indication has also received NMPA approval.9MW5211 is a highly specific, depleting novel antibody independently developed by the company. It is designed to precisely target the key pathological mechanisms mediated by abnormal immune cells in autoimmune diseases.The aberrant activation and tissue infiltration of immune cells are central drivers in the development and progression of numerous autoimmune conditions.The molecule targeted by 9MW5211 is specifically expressed on the surface of pathogenic immune cells, serving as a critical biological marker for their abnormal activation.By selectively recognizing and clearing these pathogenic cells, 9MW5211 can effectively block the immune cascade, thereby alleviating disease progression and improving clinical symptoms.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199596221","isCrawlerRequest":true}